Spruce Biosciences, Inc. (SPRB) income statement
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/30
$40.84+0.35 (+0.86%)
Close on Nov 18, 2026Market cap $117.38MP/E –Yield –
Spruce Biosciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -109.2%
Financial strength
- Current ratio
- 9.23
- Debt to equity
- 0.08
- Debt to assets
- 6.9%
- Cash to current liabilities
- 878.4%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.40
- Dividend yield
- –
See a number that looks wrong?